IGF1 and neoplasm: The acronym SAGIT® (S Signs and symptoms, A Associated comorbidities, G GH concentration either assessed as GH nadir after oral glucose tolerance test or GH random or series, I IGF-1 levels and T Tumor) refers to a pathology-specific tool first introduced in 2015 [5, 69] that aims to provide a tool to assist clinicians in assessing the acromegalic patient after initial diagnosis and during follow-up.